Neonc Technologies Holdings Inc (NTHI) Stock Price, Quote & News

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 663 7831

Website: www.neonc.com

Address:

23975 Park Sorrento, Suite 205, Calabasas, United States

NeOnc_Technologies Sep. 10 at 5:17 PM

$NTHI Our PRs don't just report encouraging Phase 2a data—it defines what comes next. With its primary endpoint achieved, survival data continuing to mature, and a differentiated intranasal platform designed to address a significant unmet need, NEO100 has now reached an important inflection point in its development. The Company's planned Type B Meeting with the FDA is expected to focus on aligning a potential registrational development path. It's the moment where years of scientific research, clinical execution, and accumulated evidence begin to translate into the next phase of the program. Every successful development program is built one milestone at a time. The latest data wasn't the finish line—it was the foundation for what comes next. $NTHI $CRSP $BEAM

0 · Reply

focafoca99 Sep. 9 at 4:27 PM

$NTHI offered a $15 million at-market registered direct offering with warrants, adding fresh capital ahead of its Phase 2a data.

1 · Reply

STACKD0E Sep. 9 at 2:48 PM

$BKSY $NTHI 👁

0 · Reply

StocktwitsNews Sep. 9 at 1:27 PM

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-holdings-inc-announces-pricing-of-15-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-with-new-and-existing-institutional-investors/cZt7d3ARJzL

0 · Reply

RomuloSkagen Sep. 9 at 11:12 AM

$NTHI anyone know if NeOnc will be presenting their 2a results at any investor conferences ? They need to get out there.

0 · Reply

RomuloSkagen Sep. 9 at 3:14 AM

$NTHI added at $4. Let’s go!

0 · Reply

NeOnc_Technologies Sep. 8 at 7:46 PM

$NVDA The latest PR marks more than a clinical milestone—it outlines the program's next regulatory step. Following the Phase 2a results, NeOnc intends to request a Type B Meeting with the FDA to align on a registrational development path. $NTHI

0 · Reply

focafoca99 Sep. 8 at 12:52 PM

$NTHI announced Phase 2a results showing 48.9% 6-month PFS, double the benchmark, and plans a Type B FDA meeting.

0 · Reply

NeOnc_Technologies Sep. 3 at 2:37 PM

$NVDA The latest PR highlights more than a clinical milestone—it addresses one of the biggest unmet needs in neuro-oncology. Patients with recurrent high-grade glioma still have no FDA-approved targeted therapy, leaving physicians with limited treatment options once the disease returns. That's why clinical innovation in this space matters. Every program that generates meaningful evidence helps advance the search for better treatment options in a disease that has seen little therapeutic progress. NeOnc's focus is to pursue new treatment approaches where patients still have few therapeutic options. $NTHI $SMMT $IOVA

0 · Reply

NeOnc_Technologies Sep. 1 at 3:24 PM

$NVDA Some of the biggest opportunities in medicine begin where treatment options remain limited. For recurrent high-grade glioma, there is still no FDA-approved targeted therapy, making it one of the most significant unmet needs NEO100 was designed to address. $NTHI

0 · Reply

NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data

2026-09-09T12:25:39.000Z - 4 days ago

NeOnc Technologies prices 3.57M shares at $4.20 in registered direct offering

Sep 9, 2026, 8:00 AM EDT - 4 days ago

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors

Sep 8, 2026, 8:39 AM EDT - 5 days ago

NeOnc' Phase 2 Data Could Put Cancer on the Ropes

Aug 28, 2026, 10:07 AM EDT - 16 days ago

NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger

Aug 26, 2026, 9:39 AM EDT - 18 days ago

NeOnc's Clinical Story Is Now the Main Event

Aug 18, 2026, 10:18 AM EDT - 26 days ago

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't

Aug 17, 2026, 3:26 PM EDT - 27 days ago

These Nasdaq Stories Are Heating Up

Aug 17, 2026, 8:45 AM EDT - 27 days ago

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

2026-08-17T09:20:34.000Z - 27 days ago

NeOnc says Phase 2a portion of NEO100-01 study met primary endpoint

Aug 14, 2026, 1:00 PM EDT - 4 weeks ago

NeOnc Technologies Holdings Transcript: AGM 2026

Aug 13, 2026, 4:18 PM EDT - 4 weeks ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Aug 13, 2026, 2:31 PM EDT - 4 weeks ago

The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

Aug 12, 2026, 9:38 AM EDT - 4 weeks ago

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

Aug 12, 2026, 9:25 AM EDT - 4 weeks ago

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

NeOnc Technologies Holdings Transcript: Study result

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

NeOnc Technologies Holdings Press release: Study result

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Aug 11, 2026, 8:44 AM EDT - 4 weeks ago

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

Aug 10, 2026, 9:00 AM EDT - 4 weeks ago

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

Aug 10, 2026, 8:30 AM EDT - 4 weeks ago

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

NeOnc Technologies Holdings Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

NeOnc Technologies Holdings Earnings release: Q2 2026

Jul 27, 2026, 9:00 AM EDT - 6 weeks ago

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

Jul 15, 2026, 9:00 AM EDT - 2 months ago

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

Jul 1, 2026, 9:32 AM EDT - 2 months ago

Wall Street is Watching These Biotechs

ELAB

Jun 24, 2026, 8:45 AM EDT - 2 months ago

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

Jun 23, 2026, 9:00 AM EDT - 2 months ago

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

Jun 23, 2026, 8:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 23, 2026, 8:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 22, 2026, 8:45 AM EDT - 2 months ago

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

Jun 17, 2026, 9:18 AM EDT - 2 months ago

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Jun 16, 2026, 1:49 PM EDT - 2 months ago

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

Jun 16, 2026, 9:00 AM EDT - 2 months ago

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

2026-06-15T20:31:23.000Z - 2 months ago

NeOnc Technologies files to sell 555,554 shares of common stock for holders

Jun 15, 2026, 8:35 AM EDT - 3 months ago

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

Jun 15, 2026, 8:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

Jun 11, 2026, 8:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 9, 2026, 8:45 AM EDT - 3 months ago

The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade

May 29, 2026, 9:05 AM EDT - 3 months ago

The Next Great AI Revolution May Be Drug Delivery

May 19, 2026, 10:28 AM EDT - 3 months ago

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

2026-05-19T11:05:51.000Z - 3 months ago

NeOnc Technologies initiated with a Buy at Alliance Global

May 18, 2026, 9:00 AM EDT - 3 months ago

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

2026-05-18T12:00:00.000Z - 3 months ago

NeOnc Technologies initiated with a Buy at Maxim

May 18, 2026, 7:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Quarterly report: Q1 2026

May 7, 2026, 8:45 AM EDT - 4 months ago

Biotech's Next Wave May Already be in Motion

May 6, 2026, 8:35 AM EDT - 4 months ago

Where Executives Are Doubling Down on Their Companies' Fortunes

May 5, 2026, 9:00 AM EDT - 4 months ago

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

2026-04-24T10:17:12.000Z - 4 months ago

NeOnc Technologies initiated with a Buy at BTIG

2026-04-10T21:20:42.000Z - 5 months ago

NeOnc Technologies files to sell 680,558 shares of common stock for holders

Apr 10, 2026, 8:00 AM EDT - 5 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

2026-04-02T17:07:18.000Z - 5 months ago

NeOnc Technologies files $300M mixed securities shelf

Apr 2, 2026, 8:00 AM EDT - 5 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

Apr 1, 2026, 9:00 AM EDT - 5 months ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Apr 1, 2026, 7:00 AM EDT - 5 months ago

NeOnc Technologies Holdings Earnings release: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 5 months ago

NeOnc Technologies Holdings Annual report: Q4 2025

2026-03-13T13:05:36.000Z - 6 months ago

NeOnc Technologies appoints Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 6 months ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 12, 2026, 8:52 AM EDT - 6 months ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

2026-03-04T13:06:31.000Z - 6 months ago

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

Mar 4, 2026, 8:00 AM EST - 6 months ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

Feb 27, 2026, 9:00 AM EST - 6 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

2026-02-06T21:55:14.000Z - 7 months ago

NeOnc Technologies files to sell 2.95M shares of common stock for holders

Feb 6, 2026, 7:00 AM EST - 7 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

2026-01-30T14:17:11.000Z - 7 months ago

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

Jan 30, 2026, 9:00 AM EST - 7 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 9, 2026, 7:32 PM EST - 8 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

2025-12-15T14:16:09.000Z - 9 months ago

NeOnc Technologies announces updated NEO100 clinical results

Dec 15, 2025, 9:00 AM EST - 9 months ago

NeOnc Technologies Reports Updated Clinical Results

2025-12-15T13:00:48.000Z - 9 months ago

NeOnc Technologies files to sell 111.7K shares of common stock for holders

Dec 15, 2025, 7:00 AM EST - 9 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

2025-12-01T14:10:42.000Z - 9 months ago

NeOnc Technologies announces preclinical findings from USC collaboration

Dec 1, 2025, 9:00 AM EST - 9 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Nov 14, 2025, 7:00 AM EST - 10 months ago

NeOnc Technologies Holdings Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

NeOnc Technologies Holdings Quarterly report: Q3 2025

2025-11-13T14:16:23.000Z - 10 months ago

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

Nov 13, 2025, 9:00 AM EST - 10 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

2025-11-12T13:26:29.000Z - 10 months ago

NeOnc announces updated results Phase 1/2a, compassionate care studies

Nov 7, 2025, 9:00 AM EST - 10 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

2025-11-04T14:05:59.000Z - 10 months ago

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

2025-10-28T13:10:14.000Z - 10 months ago

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

Oct 9, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Sep 29, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 10, 2025, 9:40 AM EDT - 1 year ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

Sep 10, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Aug 25, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 19, 2025, 7:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Earnings release: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Quarterly report: Q2 2025

Aug 11, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc_Technologies Sep. 10 at 5:17 PM

0 · Reply

focafoca99 Sep. 9 at 4:27 PM

$NTHI offered a $15 million at-market registered direct offering with warrants, adding fresh capital ahead of its Phase 2a data.

1 · Reply

STACKD0E Sep. 9 at 2:48 PM

$BKSY $NTHI 👁

0 · Reply

StocktwitsNews Sep. 9 at 1:27 PM

0 · Reply

RomuloSkagen Sep. 9 at 11:12 AM

$NTHI anyone know if NeOnc will be presenting their 2a results at any investor conferences ? They need to get out there.

0 · Reply

RomuloSkagen Sep. 9 at 3:14 AM

$NTHI added at $4. Let’s go!

0 · Reply

NeOnc_Technologies Sep. 8 at 7:46 PM

0 · Reply

focafoca99 Sep. 8 at 12:52 PM

$NTHI announced Phase 2a results showing 48.9% 6-month PFS, double the benchmark, and plans a Type B FDA meeting.

0 · Reply

NeOnc_Technologies Sep. 3 at 2:37 PM

0 · Reply

NeOnc_Technologies Sep. 1 at 3:24 PM

0 · Reply

NeOnc_Technologies Aug. 31 at 8:14 PM

$NTHI The latest PR highlights more than clinical results—it reinforces the scientific rationale behind NEO100's development. One of the biggest challenges in brain cancer isn't identifying promising therapies, but delivering them across the blood-brain barrier to reach the tumor. NEO100 was specifically designed as an intranasal therapy to bypass that barrier, representing a different approach to drug delivery than conventional systemic administration. That strategy reflects NeOnc's focus on addressing one of the fundamental limitations in treating brain tumors. Innovation in brain cancer isn't only about discovering new molecules—it's also about finding better ways to deliver them where they're needed most. $NTHI $SMMT $CGON

0 · Reply

NeOnc_Technologies Aug. 28 at 6:55 PM

$NVDA The recent NEO100 Phase 2a readout marked an important step in the program's clinical development and its progress toward the next regulatory milestones. Since the Phase 2a results, multiple SEC Form 4 filings have disclosed open-market purchases by CEO Thomas Chen and President & CEO Amir Heshmatpour, including a subsequent filing reporting an additional purchase by Dr. Chen. Insider purchases are one of the few objective corporate actions investors can evaluate alongside clinical execution, providing additional context as the program continues to advance. Clinical development is built one milestone at a time. We remain focused on advancing NEO100 through disciplined clinical execution while continuing to communicate our progress with transparency. $NTHI $MRK $SMMT

0 · Reply

focafoca99 Aug. 26 at 1:59 PM

$NTHI shows NEO100 Phase 2a hit 48.9% six-month PFS vs. 20% benchmark; FDA Type B meeting plans add a next catalyst.

0 · Reply

Bio_Invest101 Aug. 25 at 12:45 PM

$NTHI Who’s behind This 1-share plays PM ? The strong Ph2 data has no more updates in development? That Duke chief oncologist is no joke

0 · Reply

SaySomethingNice Aug. 24 at 7:08 PM

$NTHI I like this stock alot. Ceo and insidersnscooping up cheap shares. Also, expert giving the stock $15-$20+ pps ahead..

0 · Reply

copytheinsider Aug. 23 at 6:22 PM

$NTHI

0 · Reply

CEOBuysDisclosures Aug. 21 at 3:20 AM

$NTHI CEO purchased 12,757 shares at $5.49 for a total of $69,998. CHEN THOMAS C now owns 4,674,788 shares. https://ceo-buys.com

0 · Reply

AlertsAndNews Aug. 21 at 2:37 AM

$NTHI some CEO insider action here NeOnc Technologies Holdings: Thomas C. Chen (Director, CEO, 10%+) Buys 12,757 Shares @ Average Price of $5.49 (Form 4)

0 · Reply

NeOnc_Technologies Aug. 20 at 3:38 PM

$NVDA One of the biggest challenges in brain cancer isn't treating the disease—it's reaching it. NEO100's intranasal delivery was designed to bypass the blood-brain barrier and deliver therapy directly to the brain. That's the foundation of NeOnc's approach to developing therapies for patients with limited treatment options. $NTHI $CGON $MRK

0 · Reply

NeOnc_Technologies Aug. 19 at 7:14 PM

$NVDA Clinical evidence doesn't stop on the day results are announced. Alongside a median overall survival of 26.1 months, five patients remain on NEO100, allowing the program to continue building long-term clinical evidence. $NTHI

1 · Reply

CEOBuysDisclosures Aug. 18 at 10:15 PM

$NTHI CEO purchased 36,259 shares at $3.86 for a total of $140,000. CHEN THOMAS C now owns 4,660,135 shares. https://ceo-buys.com

0 · Reply

CEOBuysDisclosures Aug. 18 at 8:40 PM

$NTHI CEO purchased 9,000 shares at $5.54 for a total of $49,860. Heshmatpour Amir F now owns 7,616,140 shares. https://ceo-buys.com

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	9,700
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A